| Patient gp Active LN (NR/Relapse) Inactive LN (CR/PR) |
Parameters |
Baseline n=47 |
2 months n=29 n=18 |
4 months n=19 n=28 |
Active LN
Inactive LN |
Systolic blood pressure (mmHg) |
128 ± 13.16 |
131.69 ± 12.62
121.86 ± 11.73 |
130.23 ± 12.51
123.33 ± 11.87 |
| |
Inter group p value |
|
0.01 |
0.01 |
Active LN
Inactive LN |
Diastolic blood pressure (mmHg) |
77.80 ± 10.31 |
80.73 ± 10.76
72.73 ± 8.25 |
81.15 ± 7.86
73.14 ± 9.01 |
| |
Inter group p value |
|
0.03 |
0.77 |
Active LN
Inactive LN |
Serum albumin
(35–50 g/L) |
37.78 ± 5.54 |
37.60 ± 5.02
40.93 ± 2.54 |
36.92 ± 2.53
40.66 ± 3.74 |
| |
Inter group p value |
|
0.01 |
0.01 |
Active LN
Inactive LN |
Serum creatinine
(44–80 µmol/L) |
69 (IQR 33–252) |
81.97 (IQR 40–244)
67 (IQR 44–139) |
86 (IQR, 48–224)
62 (IQR 41–143) |
| |
Inter group p value |
|
0.43 |
0.01 |
Active LN
Inactive LN |
eGFR
(60 ml /min /1.73 m2) |
93.61 ± 46.01 |
88.56 ± 40.88
97.93 ± 31.81 |
71.15 ± 29.20
99 ± 38.15 |
| |
Inter group p value |
|
0.28 |
0.01 |
Active LN
Inactive LN |
ESR |
38.5 (IQR 21–91) |
45 (IQR 22–92)
55 (IQR 10–103) |
32 (IQR 8–105)
36.50 (IQR 1–70) |
| |
Inter group p value |
|
0.48 |
0.78 |
Active LN
Inactive LN |
Anti-dsDNA Ab titers
(<30 IU) |
35.18 (IQR 1.73–195.97) |
38.59(IQR 0.74–267.61)
13.82 (IQR 1.54–135.29) |
13.75 (IQR 2.11–175.22)
41.53 (IQR 2.07–252.85) |
| |
Inter group p value |
|
0.94 |
0.82 |
Active LN
Inactive LN |
Serum C3
(79 – 152 mg /dL) |
100.5 ± 36.39 |
96.44 ± 32.54
113 ± 43.05 |
106.06 ± 39.29
98.25 ± 21.99 |
| |
Inter group p value |
|
0.43 |
0.50 |
Active LN
Inactive LN |
Serum C4
(16 – 38 mg /dL) |
21.46 ± 12.82 |
20.08 ± 10.12
28.52 ± 16 |
22.15 ± 19.90
22.93 ± 11.77 |
| |
Inter group p value |
|
0.20 |
0.31 |
Active LN
Inactive LN |
Proteinuria (uPCI)
(< 20 mg/mmol creatinine) |
110 (IQR 10–510) |
120 (IQR 10–480)
30 (IQR 10–50) |
110 (IQR 10–510)
40 (IQR 10–50) |
| |
Inter group p value |
|
< 0.001 |
< 0.001 |
Active LN
Inactive LN |
Urinary leucocytes/HPF×106 /L |
0 (IQR 0–20) |
0 (IQR 0–20)
0 (IQR 0–10) |
0 (IQR 0–20)
0 (IQR 0–5) |
| |
Inter group p value |
|
0.31 |
0.009 |
Active LN
Inactive LN |
Urinary RBC/HPF×106 /L |
0 (IQR 0–10) |
0 (IQR 0–20)
0 (IQR 0–5) |
0 (IQR 0–50)
0 (IQR 0–20) |
| |
Inter group p value |
|
0.29 |
0.23 |
Active LN
Inactive LN |
uNGAL
(ng/ mg creatinine) |
195.80 (IQR 21.07–1413) |
187.33 (IQR 58.57–993)
117.9 (IQR 18.33–324) |
141.6 (IQR 40–526)
74.94 (IQR 21.50–605) |
| |
Inter group p value |
|
0.03 |
0.004 |
Active LN
Inactive LN |
SLEDAI-2K
(global: 0 – 105) |
8 (IQR 0–18) |
6 (IQR 0–18)
0 (IQR 0–12) |
8 (IQR 4–16)
2 (IQR 0–12) |
| |
Inter group p value |
|
< 0.001 |
< 0.001 |
Active LN
Inactive LN |
SLEDAI-2K
(renal: 0 – 16) |
4 (IQR 0–16) |
4 (IQR 0–12)
0 (IQR 0–8) |
4 (IQR 4–16)
0 (IQR 0–12) |
| |
Inter group p value |
|
<0.001 |
<0.001 |
Active LN
Inactive LN |
SLEDAI-2K
(extrarenal: 0 – 89) |
4 (IQR 0–12) |
2 (IQR 0–10)
0 (IQR 0–8) |
4 (IQR 0–8)
2 (IQR 0–4) |
| |
Inter group p value |
|
0.10 |
0.65 |
Gp: group; Calcineurin inhibitors: Cyclosporine A/ Tacrolimus; eGFR: Estimated Glomerular Filtration Rate; ESR: Erythrocyte Sedimentation Rate; anti dsDNA: anti– double-stranded DNA antibody; C3: Complement 3; C4: Complement 4; SLEDAI-2K: Systemic Lupus Erythematosus Disease Activity Index-2K; uPCI: Urine Protein Creatinine Index; uNGAL: Urine Neutrophil Gelatinase Associated Lipocalin